183 related articles for article (PubMed ID: 35649245)
21. Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients.
Milligan C; Atassi N; Babu S; Barohn RJ; Caress JB; Cudkowicz ME; Evora A; Hawkins GA; Wosiski-Kuhn M; Macklin EA; Shefner JM; Simmons Z; Bowser RP; Ladha SS
Muscle Nerve; 2021 Sep; 64(3):309-320. PubMed ID: 34075589
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity.
Li Z; Hao Y; Yang C; Yang Q; Wu S; Ma H; Tian S; Lu H; Wang J; Yang T; He S; Zhang X
Eur J Med Chem; 2022 Jan; 228():114036. PubMed ID: 34906762
[TBL] [Abstract][Full Text] [Related]
23. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.
Hua X; Church K; Walker W; L'Hostis P; Viardot G; Danjou P; Hendrix S; Moebius HJ
J Alzheimers Dis; 2022; 86(3):1399-1413. PubMed ID: 35180125
[TBL] [Abstract][Full Text] [Related]
24. Genetic Inhibition of Receptor Interacting Protein Kinase-1 Reduces Cell Death and Improves Functional Outcome After Intracerebral Hemorrhage in Mice.
Lule S; Wu L; McAllister LM; Edmiston WJ; Chung JY; Levy E; Zheng Y; Gough PJ; Bertin J; Degterev A; Lo EH; Whalen MJ
Stroke; 2017 Sep; 48(9):2549-2556. PubMed ID: 28765287
[TBL] [Abstract][Full Text] [Related]
25. Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).
Mandrioli J; Crippa V; Cereda C; Bonetto V; Zucchi E; Gessani A; Ceroni M; Chio A; D'Amico R; Monsurrò MR; Riva N; Sabatelli M; Silani V; Simone IL; Sorarù G; Provenzani A; D'Agostino VG; Carra S; Poletti A
BMJ Open; 2019 May; 9(5):e028486. PubMed ID: 31152038
[TBL] [Abstract][Full Text] [Related]
26. The Receptor-interacting Serine/Threonine Protein Kinase 1 (RIPK1) Regulates Progranulin Levels.
Mason AR; Elia LP; Finkbeiner S
J Biol Chem; 2017 Feb; 292(8):3262-3272. PubMed ID: 28069809
[TBL] [Abstract][Full Text] [Related]
27. Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation.
Newton K
Cold Spring Harb Perspect Biol; 2020 Mar; 12(3):. PubMed ID: 31427374
[TBL] [Abstract][Full Text] [Related]
28. Identification of an antibody-based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues.
Finger JN; Brusq JM; Campobasso N; Cook MN; Deutsch J; Haag H; Harris PA; Jenkins EL; Joglekar D; Lich JD; Maguire S; Nagilla R; Rivera EJ; Sun H; Votta BJ; Bertin J; Gough PJ
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226625
[TBL] [Abstract][Full Text] [Related]
29. A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.
Weisel K; Berger S; Thorn K; Taylor PC; Peterfy C; Siddall H; Tompson D; Wang S; Quattrocchi E; Burriss SW; Walter J; Tak PP
Arthritis Res Ther; 2021 Mar; 23(1):85. PubMed ID: 33726834
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
31. Axonal Degeneration: RIPK1 Multitasking in ALS.
Politi K; Przedborski S
Curr Biol; 2016 Oct; 26(20):R932-R934. PubMed ID: 27780064
[TBL] [Abstract][Full Text] [Related]
32. MK2 phosphorylation of RIPK1 regulates TNF-mediated cell death.
Dondelinger Y; Delanghe T; Rojas-Rivera D; Priem D; Delvaeye T; Bruggeman I; Van Herreweghe F; Vandenabeele P; Bertrand MJM
Nat Cell Biol; 2017 Oct; 19(10):1237-1247. PubMed ID: 28920952
[TBL] [Abstract][Full Text] [Related]
33. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
Scheltens P; Hallikainen M; Grimmer T; Duning T; Gouw AA; Teunissen CE; Wink AM; Maruff P; Harrison J; van Baal CM; Bruins S; Lues I; Prins ND
Alzheimers Res Ther; 2018 Oct; 10(1):107. PubMed ID: 30309389
[TBL] [Abstract][Full Text] [Related]
34. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
Hou J; Ju J; Zhang Z; Zhao C; Li Z; Zheng J; Sheng T; Zhang H; Hu L; Yu X; Zhang W; Li Y; Wu M; Ma H; Zhang X; He S
Cell Death Dis; 2019 Jun; 10(7):493. PubMed ID: 31235688
[TBL] [Abstract][Full Text] [Related]
35. A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.
Weisel K; Scott N; Berger S; Wang S; Brown K; Powell M; Broer M; Watts C; Tompson DJ; Burriss SW; Hawkins S; Abbott-Banner K; Tak PP
BMJ Open Gastroenterol; 2021 Aug; 8(1):. PubMed ID: 34389633
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
[TBL] [Abstract][Full Text] [Related]
37. CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens.
Ishii T; Okai T; Iwatani-Yoshihara M; Mochizuki M; Unno S; Kuno M; Yoshikawa M; Shibata S; Nakakariya M; Yogo T; Kawamoto T
Sci Rep; 2017 Oct; 7(1):13000. PubMed ID: 29026104
[TBL] [Abstract][Full Text] [Related]
38. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
[TBL] [Abstract][Full Text] [Related]
39. When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157.
Rojas-Rivera D; Delvaeye T; Roelandt R; Nerinckx W; Augustyns K; Vandenabeele P; Bertrand MJM
Cell Death Differ; 2017 Jun; 24(6):1100-1110. PubMed ID: 28452996
[TBL] [Abstract][Full Text] [Related]
40. Genetic Regulation of RIPK1 and Necroptosis.
Xu D; Zou C; Yuan J
Annu Rev Genet; 2021 Nov; 55():235-263. PubMed ID: 34813352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
